A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Olaparib
Related studies linked through entity extraction aliases.
A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of Tremelimumab Alone or Combined With Olaparib for Patients With Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma)
- Status
- TERMINATED
- Phase
- PHASE1
Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Platine, Avastin and OLAparib in 1st Line
- Status
- COMPLETED
- Phase
- PHASE3
To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer
- Status
- COMPLETED
- Phase
- PHASE4
Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
The Pharmacokinetics and Safety of Olaparib Alone and With Paclitaxel in Chinese Patients With Advanced Solid Tumour.
- Status
- COMPLETED
- Phase
- PHASE1
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
- Status
- TERMINATED
- Phase
- PHASE1
Trabectedin Plus Olaparib in Metastatic or Advanced Sarcomas (TOMAS)
- Status
- COMPLETED
- Phase
- PHASE1
Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations
- Status
- WITHDRAWN
- Phase
- PHASE3
Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib
- Status
- COMPLETED
- Phase
- PHASE2
Trial of Olaparib in Combination with AZD5363 (ComPAKT)
- Status
- COMPLETED
- Phase
- PHASE1
Study of Olaparib (± Degarelix) Given to Men With Intermediate/High Risk Prostate Cancer Before Prostatectomy
- Status
- COMPLETED
- Phase
- PHASE1
Phase I Study of Olaparib Combined With Cisplatin-based Chemoradiotherapy to Treat Locally Advanced Head and Neck Cancer
- Status
- COMPLETED
- Phase
- PHASE1
SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments
- Status
- COMPLETED
- Phase
- PHASE3
Olaparib and Radiotherapy in Head and Neck Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1